Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Genhouse Bio Raises RMB 300 Million in Cross‑Over Round Led by Green Pine Capital

Fineline Cube Jan 14, 2026
Company Deals

Iktos and Servier Forge EUR 1 Billion+ AI Drug Discovery Collaboration

Fineline Cube Jan 14, 2026
Company Deals

Hisoar Pharma Invests RMB 150 Million in Wanbangde’s WP205 for ALS, Securing 15 % Global Revenue Share

Fineline Cube Jan 13, 2026
Company Deals

Bayer AG Acquires Cardiac Amyloidosis Imaging Tracers from Attralus, Including Phase III AT‑01 with FDA Breakthrough Designation

Fineline Cube Jan 13, 2026
Company Deals

RemeGen Licenses RC148 Bispecific to AbbVie for Up to $5.6 Billion in Milestones

Fineline Cube Jan 13, 2026
Policy / Regulatory

NHSA Launches 6th VBP Tender for Medical Consumables in China, Targeting Drug-Coated Balloons

Fineline Cube Jan 13, 2026
Company Drug

Haichang Biotech’s HC016 Receives FDA Orphan Drug Designation for Osteosarcoma

Fineline Cube Jan 14, 2026
Company Drug

Sanofi’s Teizeild Wins EU Approval as First Disease‑Modifying Therapy for Type 1 Diabetes

Fineline Cube Jan 13, 2026
Company Deals Drug

Hua Medicine and Bayer AG Terminate Co-promotion Agreement for HuaTangNing

Fineline Cube Nov 22, 2024

China-based Hua Medicine (HKG: 2552) has announced the termination of its co-promotion agreement with German...

Company Medical Device

United Imaging Installs AI-Powered uMR OMEGA at XRANM’s Breast Health Center

Fineline Cube Nov 22, 2024

Shanghai-based United Imaging Healthcare Co., Ltd. has announced the installation of an ultra-wide-bore AI-empowered uMR...

Company Drug

Sino Biopharmaceutical Submits NDA for Anlotinib and Penpulimab Combo in HCC to NMPA

Fineline Cube Nov 21, 2024

China-based Sino Biopharmaceutical Ltd (HKG: 1177) has announced the submission of a New Drug Application...

Company Deals

Sihuan Pharmaceutical’s Huisheng Pharm Strikes Exclusive Deal for Semaglutide Biosimilar in China

Fineline Cube Nov 21, 2024

China’s Sihuan Pharmaceutical Holdings Group Ltd (HKG: 0460) has announced an exclusive licensing agreement between...

Company Drug

Innovent Biologics’ IBI354 Earns Breakthrough Therapy Designation for Ovarian Cancer Treatment

Fineline Cube Nov 21, 2024

The Center for Drug Evaluation (CDE) website has indicated that China-based Innovent Biologics, Inc. (HKG:...

Company Drug

CDE Includes Double-Crane’s Hydroxocobalamine and Sanofi Genzyme’s Fitusiran in Rare Disease Care Plan

Fineline Cube Nov 21, 2024

China’s Center for Drug Evaluation (CDE) has announced the inclusion of China Resources Double-Crane Pharmaceutical...

Company Drug

Apeiron Therapeutics Initiates Phase Ia/B Study for GTA182 in Solid Tumors with MTAP Deficiency

Fineline Cube Nov 21, 2024

Apeiron Therapeutics, a biomarker-driven cancer therapy developer with operations in Shanghai, China, and San Francisco,...

Company Deals

BI Partners with Sinopharm for Promotion of Sifrol and Pradaxa in China

Fineline Cube Nov 21, 2024

German pharmaceutical major Boehringer Ingelheim (BI) has entered into a partnership with China-based Sinopharm Group...

Company Medical Device

Medtronic Receives US Approval for InPen App with Missed Meal Dose Detection

Fineline Cube Nov 21, 2024

US-Irish firm Medtronic (NYSE: MDT) has announced US market approval for its new InPen app,...

Company Deals

CStone Pharmaceuticals Partners with Pharmalink for Suemalimab Commercialization in MENA and South Africa

Fineline Cube Nov 21, 2024

China-based CStone Pharmaceuticals (HKG: 2616) has announced a strategic commercial collaboration with Pharmalink Store –...

Company Drug

NMPA Approves Alpha Biopharma’s Zorifertinib for First-Line NSCLC Treatment with CNS Metastases

Fineline Cube Nov 21, 2024

The National Medical Products Administration (NMPA) has granted approval to China-based Alpha Biopharma’s zorifertinib, commercially...

Company Drug

Pfizer’s Hympavzi Receives European Commission Approval for Hemophilia A and B

Fineline Cube Nov 21, 2024

US pharmaceutical major Pfizer Inc. (NYSE: PFE) has announced that the European Commission (EC) has...

Company Drug

Guangdong Zhongsheng Pharmaceutical’s RAY1225 Shows Positive Results in Phase II Study

Fineline Cube Nov 21, 2024

Guangdong Zhongsheng Pharmaceutical Co., Ltd (SHE: 002317), a China-based pharmaceutical company, has announced positive top-line...

Company Deals

Shenzhen Chipscreen Biosciences Announces Private Placement to Fund Drug R&D and Expansion

Fineline Cube Nov 21, 2024

China-based biopharmaceutical company Shenzhen Chipscreen Biosciences Co., Ltd (SHA: 688321) has announced plans for a...

Company Drug

US FDA Grants ODD to Ractigen’s siRNA Therapy RAG-21 for ALS Treatment

Fineline Cube Nov 21, 2024

China-based small activating RNA (saRNA) drug developer, Ractigen Therapeutics, has announced that it has received...

Company Drug

UCB’s Bimzelx Receives US FDA Approval for Moderate to Severe Hidradenitis Suppurativa

Fineline Cube Nov 21, 2024

Belgium-based biopharmaceutical company UCB (FRA: UNC) has announced that the US Food and Drug Administration...

Company Deals

Alloy Therapeutics Partners with Takeda on iPSC-Derived CAR-T and CAR-NK Therapies

Fineline Cube Nov 21, 2024

US-based Alloy Therapeutics Inc. has announced a strategic partnership with Japan-headquartered Takeda Pharmaceutical Co., Ltd...

Legal / IP

BeiGene Reaches Patent Settlement with MSN Pharmaceuticals for Brukinsa

Fineline Cube Nov 21, 2024

China-based BeiGene Ltd (NASDAQ: BGNE; HKG: 6160; SHA: 688235), which is in the process of...

Company Deals

Laekna and Eli Lilly & Co. Enter Clinical Cooperation to Advance Obesity Treatment LAE102

Fineline Cube Nov 20, 2024

Sino-US biotech company Laekna, Inc. (HKG: 2105) has announced a significant clinical cooperation agreement with...

Company Drug

GSK’s Linerixibat Demonstrates Efficacy in Phase III GLISTEN Study for Cholestatic Pruritus

Fineline Cube Nov 20, 2024

UK-based pharmaceutical giant GlaxoSmithKline (GSK; NYSE: GSK) has announced positive headline results from the Phase...

Posts pagination

1 … 205 206 207 … 609

Recent updates

  • Genhouse Bio Raises RMB 300 Million in Cross‑Over Round Led by Green Pine Capital
  • Haichang Biotech’s HC016 Receives FDA Orphan Drug Designation for Osteosarcoma
  • Iktos and Servier Forge EUR 1 Billion+ AI Drug Discovery Collaboration
  • Sanofi’s Teizeild Wins EU Approval as First Disease‑Modifying Therapy for Type 1 Diabetes
  • CSPC’s Prusogliptin/Metformin FDC NDA Accepted by NMPA for Type 2 Diabetes, Targeting 60 M Underserved Patients
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Genhouse Bio Raises RMB 300 Million in Cross‑Over Round Led by Green Pine Capital

Company Drug

Haichang Biotech’s HC016 Receives FDA Orphan Drug Designation for Osteosarcoma

Company Deals

Iktos and Servier Forge EUR 1 Billion+ AI Drug Discovery Collaboration

Company Drug

Sanofi’s Teizeild Wins EU Approval as First Disease‑Modifying Therapy for Type 1 Diabetes

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.